comprehensive -WSS

comprehensive

author：entertainment 2025-09-29 21:29:06 - browse：84

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： NYU radiologists take on the challenge of expensive MRI machines

hotspot

knowledge

WSS

Weight loss drug costs may need more research, senator suggests

Supreme Court strikes down Biden student loan forgiveness program

Does good food count as health care? Study aims to find out

Childhood cancer progress stalls for Black, Hispanic kids: Report

PBM reforms clear House panel

GOP inquiry over gain

entertainment

comprehensive

Wikipedia

Psychedelics group wrestles with new pharma identity

Morphosys mixed study results for blood cancer drug

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Ransomware attacks on hospitals: Study outlines patient impact

BioMarin wins approval for gene therapy to treat hemophilia A

GOP inquiry over gain

Cancer drug shortages should be causing more outrage

Poor hospice wound care hurts patients and families

leisure time

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Weight loss drug costs may need more research, senator suggests

In key trial, Verve's treatment lowers cholesterol levels in patients

Synthetic human embryos? Researchers say term is overblown

Supreme Court rules employers must be more accommodating of religious observance

knowledge

hotspot

knowledge

entertainment